EVALUATION OF CLINICAL, METABOLIC AND ULTRASONOGRAPHIC PARAMETERS OF PATIENTS WITH POLYCYSTIC OVARY SYNDROME RECEIVING VITAMIN D TREATMENT

Yıl 2023, Cilt: 9 Sayı: 3, 165 - 184, 24.12.2023

Ufuk Atlıhan Ömer Erbil Doğan

Öz

Objective: The aim of the study is the evaluation of clinical, metabolic and ultrasonographic parameters of patients with polycystic ovary syndrome, who are receiving treatment because of with vitamin D deficiency.
Materials & Method: This study was conducted after the permission was granted from the Ethics Committee for Clinical Studies of Dokuz Eylul University School of Medicine. 95 patients, who visited the reproductive endocrinology and infertility outpatient clinic of Dokuz Eylül University School of Medicine Department of Obstetrics and Gynaecology between December 1, 2013 and December 1, 2014 and were diagnosed with polycystic ovary syndrome according to Rotterdam Criteria. The clinical, metabolic and ultrasonographic parameters of the patients with polycystic ovary syndrome ,who received treatment due to vitamin D deficiency, were evaluated retrospectively.
Results: Between the weight, waist circumference, waist to hip ratio, LH, FSH, estradiol, total testosterone, prolactin, thyroid stimulating hormone, oral glucose tolerance test, insulin, 17-OH progesterone, HDL, LDL, triglyceride, total cholesterol, fasting blood glucose level, mean arterial blood pressure, androstenedione, SHBG, VKİ, HOMA-IR, total ovarian volume values of the patients in the 0th and 3rd months, the difference was insignificant. A statistically significant decrease was found in the mean Ferriman-Gallwey score, menstrual period, 25-OH vitamin D level, DHEAS level, free testosterone concentration, LH/FSH ratio, total number of antral follicles and free androgen index level. The correlation among the increase in the concentration of 25 - OH Vitamin D, the level of LH/FSH ratio, total antral follicle count, level of free androgen index and the decrease in DHEAS levels was evaluated with Pearson Correlation Analysis and no statistically significant difference was detected [(p<0,05),(r: ±1)]. The increase in 25-OH vitamin D level and the decrease Ferriman-Gallwey scores were evaluated with Pearson Correlation Analysis and the correlation was found statistically significant (p<0.024, r:-0,232).
Conclusion: After treatment with vitamin D3; no statistically significant difference was found between the lipid parameters and insulin resistance in patients with PCOS. The biochemical parameters of hyperandrogenism showed statistically significant difference after treatment. The clinical findings of the patients showed improvement after treatment; the difference in menstrual periods between before and after treatment was significant. The post-treatment ultrasonography of patients revealed significant decrease in total number of antral follicles when compared to the pre-treatment examination.

Anahtar Kelimeler

Polycystic ovary syndrome, 25-OH D vitamin

D VİTAMİNİ EKSİKLİĞİ NEDENİYLE TEDAVİ ALAN POLİKİSTİK OVER SENDROMLU HASTALARIN KLİNİK, METABOLİK VE ULTRASONOGRAFİK PARAMETRELERİNİN DEĞERLENDİRİLMESİ

Öz

Amaç: Bu çalışmada, D vitamini eksikliği nedeniyle tedavi alan polikistik over sendromlu hastaların klinik, metabolik, ultrasonografik parametrelerinin değerlendirilmesi amaçlanmıştır.
Materyal-Metod: Dokuz Eylül Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Üreme Endokrinolojisi ve İnfertilite Bilim Dalı Polikliniği’ne 01/12/2013-01/12/2014 tarihleri arasında başvuran polikistik over sendromu tanısı konulan toplam 95 hasta çalışmaya alınmıştır. D vitamini eksikliği nedeniyle tedavi alan polikistik over sendromlu hastaların 3 aylık tedavi sonrasındaki klinik, metabolik, ultrasonografik parametreleri retrospektif olarak değerlendirilmiştir.
Bulgular: Vitamin D3 kullanımı sonrasında 0.ay ve 3.ay arasında kilo,bel çevresi,kalça çevresi,bel/kalça oranı, LH, FSH, estradiol, total testosteron, PRL, TSH, OGTT düzeyi, insülin, 17-OH progesteron, HDL, LDL, trigliserit, total kolesterol, açlık kan şekeri düzeyi, ortalama arteriyal kan basıncı, androstenedion, SHBG, VKİ, HOMA-IR, total over volümü değerleri arasında anlamlı farklılık izlenmedi. Ferriman gallwey skoru, adet düzeni, 25-OH D vitamini düzeyi, DHEAS düzeyi, free testosteron, LH/FSH oranı, total antral folikül sayısı, free androjen indeks düzeyinde istatistiksel olarak anlamlı azalma saptandı. 25-OH D vitamin düzeyi artışı ile LH/FSH oranı düzeyi, total antral folikül sayısı, serbest androjen indeksi düzeyi, DHEAS düzeyi azalması korelasyonu, pearson korelasyon analizi ile değerlendirildi ve istatistiksel olarak anlamlı farklılık saptanmadı[(p<0,05),(r: ±1)]. 25-OH D vitamin düzeyi artışı ile Ferriman Gallwey skoru azalması arasında anlamlı korelasyon saptandı (p<0.024, r:-0,232).
Sonuç: Polikistik over sendromlu hastalarda vitamin D3 kullanımı sonrasında lipid parametreleri ve insülin rezistansında anlamlı bir azalma saptanmamıştır. Hiperandrojenizmin biyokimyasal parametrelerinde tedavi sonrası dönemde anlamlı azalma saptanmıştır. Hastaların menstrual sikluslarında tedavi sonrası anlamlı düzelme saptanmıştır. Hastaların tedavi sonrası yapılan ultrasonografisinde, tedavi öncesi döneme göre total antral folikül sayısında anlamlı azalma saptanmıştır.

Anahtar Kelimeler

Polikistik over sendromu, 25-OH D vitamini, ultrasonografik parametre

Kaynakça

• KAYNAKÇA 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9.
• 2. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus whorkshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycycstic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
• 3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.
• 4. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W , Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil steril. 2009;91(2):456-88.
• 5. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009;13(2):90–2.
• 6. Lord J, Wilkin T. Metformin in polycystic ovary syndrome. Curr Opin Obstet Gynecol. 2004;16(6):481–6.
• 7. Setji TL, Brown AJ. Polycystic ovary syndrome: Update on diagnosis and treatment. J Med. 2014;127(10):912-919.
• 8. O’Brien RF, Emans SJ. Polycystic ovary syndrome in adolecan 2008; 21(3):119–28.
• 9. Orio F, Azziz R. Report on the Third Annual Meeting of the Androgen Excess Society. Fertil Steril. 2006;86(5):1318–20.
• 10. De Felici M, Dolci S & Siracusa G. An increase of intracellular free Ca2C is essential for spontaneous meiotic resumption by Mouse oocytes. Journal of Experimental Zoology 1991 260 401–405.
• 11. Aleyasin A, Hosseini MA, Mahdavi A, Safdarian L, Fallahi P, Mohajeri MR, Abbasi M & Esfahani F. Predictive value of the level of vitamin D in follicular fluid on the outcome of assisted reproductive technology. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2011 159 132–137.
• 12. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Se¬rum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995; 27:181-8.
• 13. Scragg R, Sowers M, Bell C; Third National Health and Nutrition Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-8.
• 14. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Man¬son JE, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29:650-6.
• 15. Mattila C, Knekt P, Mannisto S, Rissanen H, Laaksonen MA, Mon¬tonen J, et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 2007;30:2569- 70.
• 16. Liu E, Meigs JB, Pittas AG, McKeown NM, Economos CD, Booth SL, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009;139:329-34.
• 17. Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 2010;33:234-8.
• 18. Kotsa, K., Yavropoulou, M.P., Anastasiou, O. et al. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertility and Sterility (2009) 92, 1053–1058.
• 19. Wehr, E., Pieber, T.R. & Obermayer-Pietsch, B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in PCOS women-a pilot study. Journal of Endocrinological Investigation(2011) 34, 757–763.
• 20. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P & Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999 64 430–435.
• 21. Pal, L., Shu, J., Zeitlian, G. et al. (2008) Vitamin D insufficiency in reproductive years may be contributory to ovulatory infertility and PCOS. Fertility and Sterility, 90, S14.
• 22. Rashidi, B., Haghollahi, F., Shariat, M. et al. The Effects of Calcium- Vitamin D and Metformin on Polycystic Ovary Syndrome: a Pilot Study. Taiwanese Journal of Obstetrics and Gynecology(2009), 48, 142–147
• 23. Glintborg, D., Andersen, M., Hagen, C. et al. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clinical Endocrinology (2005),62, 683–691.
• 24. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbanc¬es in polycystic ovary syndrome. Eur J Endocrinol 2009;161:575- 82.
• 25. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S, et al. Low serum 25-hydroxyvitamin D concentrations are asso¬ciated with insulin resistance and obesity in women with poly¬cystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006;114: 577-83
• 26. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011; 60:1475-81.
• 27. Mosca L., Appel LJ., Benjamin EJ. Evidence based guidelines for cardiovascular disease prevention in women. J Am. Coll Cardiol 2004; 43: 900-21.
• 28. Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG & Kamaci M. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics 2009 280 559–563.
• 29. Mazloomi S, Sharifi F, Hajihosseini R, Kalantari S, Mazloomzadeh S. Association between Hypoadiponectinemia and Low Serum Concentrations of Calcium and Vitamin D in Women with Poly¬cystic Ovary Syndrome. ISRN Endocrinol 2012;2012:949427.
• 30. Zittermann, A., Schleithoff, S.S. & Koerfer, R. Putting cardiovascular disease and vitamin D insufficiency into perspective. British Journal of Nutrition (2005),94, 483–492
• 31. Merke, J., Hofmann, W., Goldschmidt, D. et al. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcified Tissue International(1987), 41, 112–114.
• 32. Somjen, D., Weisman, Y., Kohen, F. et al. 25-hydroxyvitamin D3-1alpha hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation (2005), 111,1666–1671.
• 33. Merke, J., Milde, P., Lewicka, S. et al. Identification and regulation of 1,25 dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest(1989), 83, 1903–1915.
• 34. Wang, T.J., Pencina, M.J., Booth, S.L. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation(2008), 117, 503–511.
• 35. Scragg, R., Jackson, R., Holdaway, I.M. et al. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community based study. International Journal of Epidemiology(1990), 19, 559–563.
• 36. Giovannucci, E., Liu, Y., Hollis, B.W. et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Archives of Internal Medicine(2008), 168, 1174–1180.
• 37. Pilz, S., Dobnig, H., Nijpels, G. et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf) (2009), 71, 666–672.
• 38. Kilkkinen, A., Knekt, P., Aro, A. et al. Vitamin D status and the risk of cardiovascular disease death. American Journal of Epidemiology (2009), 170, 1032–1039.
• 39. Ginde, A.A., Scragg, R., Schwartz, R.S. et al. Prospective study of serum 25-hydroxyvitamin d level, cardiovascular disease mortality, and all-cause mortality in older U.S. Adults. J Am Geriatr Soc (2009), 57, 1595–1603.,
• 40. Mahmoudi, T. (2009) Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertility and Sterility, 92, 1381–1383.